Information for consumers
MIFEGYMISO is a combination product containing two drugs (1 mifepristone tablet and 4 misoprostol tablets) used for abortion, meaning ending a pregnancy less than 49 days from the start of the last menstrual period.
Physicians should complete a training program prior to prescribing MIFEGYMISO. Before getting MIFEGYMISO, the patient will be asked by the prescriber to review and sign a consent form and Patient Information Card.
The Patient Information Card contains the following information:
-
The follow-up appointment location, date and time;
-
Contact information in case the patient needs to call the doctor or clinic;
-
Where the patient should go in case of an emergency;
-
The manufacturer’s 24 hour support line 1-877-230-4227. The patients can call this number when they need assistance but they cannot reach their own doctor or clinic.
The prescriber will also give the patient a printed copy of the Patient Medication Guide, a document that includes detailed information on MIFEGYMISO.
Patients should contact a healthcare professional if they are experiencing a side effect related to MIFEGYMISO use or if they wish to obtain additional information on the use of MIFEGYMISO and its safety.
Follow-up is important to confirm whether the pregnancy has completely ended and to verify that there is no prolonged heavy bleeding or infection.
Information for healthcare professionals
Practice of medicine and pharmacy may vary by province. In addition to the information below, different healthcare professional associations, such as the College of Physicians and Surgeons of British Columbia, the College of Pharmacists of British Columbia, as well as the College of Physicians and Surgeons and the College of Pharmacists of Ontario, have issued communications to their members regarding the associations’ recommended approach for the dispensing of MIFEGYMISO.
Prescribing Physicians
An Education Program developed by Society of Obstetricians and Gynaecologists of Canada (SOGC) in collaboration with the College of Family Physicians of Canada (CFPC) and the Canadian Pharmacists Association (CPhA) is available to prescribing physicians.
Prescribing physicians should complete Module 5 of either the Accredited (paid access) OR Non-Accredited (free access) Medical Abortion Training Program, available on the
SOGC Online courses website, before prescribing, ordering, stocking (if applicable), and/or dispensing MIFEGYMISO. Completion of Module 5 takes less than an hour.
-
Upon completion of Module 5, the physician will receive information on how to order Patient Consent Forms, printed copies of the Patient Medication Guide, and Patient Information Cards, directly from Celopharma. Information can also be obtained on how to order MIFEGYMISO.
-
Prescribers stocking MIFEGYMISO may dispense the medication directly to the woman, where permitted under provincial/territorial law. Alternatively, a prescriber may send a prescription (by fax, verbal prescription or written prescription) to a pharmacy that stocks MIFEGYMISO. The box may then be shipped back to the prescriber office for delivery to the woman.
-
Prescribers are encouraged to engage in proactive communication with nearby or local pharmacists/pharmacies to identify pharmacies that stock MIFEGYMISO.
As per the approved Canadian Product Monograph, in addition to completing the MIFEGYMISO education and registration programs, prescribers have to do the following prior to prescribing MIFEGYMISO:
-
Ensure that patients have access to emergency medical care in the 14 days following administration of mifepristone;
-
Schedule follow-up 7 to 14 days after patients take mifepristone to confirm complete pregnancy termination;
-
Exclude ectopic pregnancy and confirm gestational age by ultrasound;
-
Counsel each patient on the risks and benefits of MIFEGYMISO, including bleeding, infection, and incomplete abortion;
-
Obtain the patient’s written informed consent to take the drug;
-
Complete the Patient Information Card that is in the MIFEGYMISO box or ordered directly from Celopharma.
Each patient must be provided with a printed copy of the Mifegymiso Patient Medication Guide.
Follow-up is important to confirm pregnancy termination and complete abortion and to ensure that the patient is not experiencing any of the serious adverse reactions associated with MIFEGYMISO use, such as excessive bleeding or infection/sepsis. MIFEGYMISO treatment failure may require the surgical termination of the pregnancy.
Educational and Information Tools for women
The
Patient Medication Guide must be given to women having a medical abortion. It includes information on the drugs to be used, the procedure to be followed before taking the drugs, how to take the drugs, signs and symptoms of the termination, possible side effects, and follow-up.
The
Patient Consent Form is provided for signature by the patient and the prescriber. The signed Consent Form should be retained in the patient’s file. The Patient Consent Form is not required to be provided to the pharmacist for the filling of the prescription.
The
Patient Information Card should be filled in by the prescriber and given to the patient and is signed by both the prescriber and the patient. It includes information on: the date and time of the treatment; the follow-up appointment date and time; and the emergency contact information. The Patient Information Card is located inside MIFEGYMISO box or for order directly from Celopharma.
Revised Patient Medication Information
The box labels and package inserts currently being distributed
may not accurately reflect the terms of the revised Product Monograph. See above (Background, Revised Patient Medication Information) for additional information.
Pharmacists and Pharmacies
Module 5 of the Medical Abortion Training Program, available on the
SOGC Online courses Web site, is available for pharmacists and, while it is not mandatory, they are encouraged to follow the Training Program prior to setting up an account with Celopharma and ordering and stocking MIFEGYMISO.
Other resources available to healthcare professionals
MIFEGYMISO providers can consider registering with the
Canadian Abortion Providers Support, a university-based Canadian online community for health professionals that is managed in collaboration with the SOGC, CFPC and CPhA. Practice guidelines, a map of pharmacies stocking MIFEGYMISO, patient handouts, the latest information on subsidy options for mifepristone, and “Ask-an-Expert” features are available to support professionals.